ArticleTechniques in coloproctology2026
Use of artificial intelligence in analysis of endoscopic images to detect residual disease or regrowth in rectal patients with complete clinical response to neoadjuvant chemoradiotherapy.
Article in Techniques in coloproctology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with rectal cancer who have a complete clinical response (cCR) to neoadjuvant chemo/radiotherapy (nCRT) may opt for organ preservation and watch and wait (W&W). This consists of an intense surveillance program including serial endoscopies, pelvic magnetic resonance imaging (MRI), carcinoembryonic antigen (CEA), and computed tomography (CT) scans to detect regrowth at an early stage. However, residual lesions or regrowths can be challenging to identify endoscopically, due to mucosal changes such as friability and neovascularization. We developed a novel deep learning model to assist in the detection of residual or regrown rectal cancer lesions during proctosigmoidoscopy.
methodsWe trained a convolutional neural network (Wide ResNet-101-2) on a dataset of 1795 annotated frames from proctosigmoidoscopy exams of 97 patients treated at a tertiary referral center. Residual or regrowth was defined by histopathological confirmation. The dataset was split into training and testing cohorts using a 90/10% patient-level split.
resultsOut of 97 patients, 24 (363 frames) had confirmed residual disease or regrowths, while 73 (1432 frames) presented normal rectal mucosa. The model achieved an overall accuracy of 92.8%, with a sensitivity of 80.0%, specificity of 97.3%, positive predictive value (PPV) of 90.9%, negative predictive value (NPV) of 94.0%, and an area under the receiver operating characteristic curve (AUROC) of 0.886.
conclusionsTo the best of our knowledge, this is the first deep learning model specifically developed for the detection of residual disease or regrowth following cCR in W&W patients during endoscopic examination. This tool has the potential to aid lesion detection, guide clinical decision-making, and increase opportunities for salvage, curative treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.